Ascletis Pharma Berita Eulerpool

Ascletis Pharma Eulerpool News

Ascletis Pharma Berita Saham

Ascletis Pharma diawasi oleh banyak jurnalis dan investor di seluruh dunia. Berita terkini Ascletis Pharma kami rangkum di sini.

• 17 September ·

  Yahoo
  Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
• 31 Juli ·

  SeekingAlpha
  Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
• 11 Juni ·

  Yahoo
  Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
• 3 April ·

  Yahoo
  Ascletis Announces Strategic Decisions on FXR agonist ASC42
• 11 Maret ·

  Yahoo
  Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
• 28 Januari ·

  SeekingAlpha
  Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
• 24 Januari ·

  Yahoo
  Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
• 23 Januari ·

  Yahoo
  Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
• 2 Januari ·

  Yahoo
  Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
• 5 Desember ·

  Yahoo
  Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne